Sandbox Reserved 1658: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 50: | Line 50: | ||
== Applications == | == Applications == | ||
<p align="justify">NRP1 targeting is investigated as a possible cancer therapy. Several methods have been developed to inhibit the oncogenic activities of NRP1 by using iRNA, monoclonal antibodies or even peptides. Especially, monoclonal antibodies are experimented as antitumor agents. Some have already being developed such as specific CUB antibodies and anti-NRP1B that inhibit cell migration induced by VEGF and the formation of tumors in endothelial cells.</p> | |||
== References == | == References == | ||
<references/> | <references/> | ||
